

17 April 2020

May 2020 Pharmaceutical Schedule Dispatch

This dispatch email is provided to pharmacists as an early notification of the changes to be announced in the **May 2020** Update to the Pharmaceutical Schedule.

New listings

- Amino acid formula (Neocate SYNEO) powder (unflavoured), 400 g OP – Special Authority – Hospital pharmacy [HP3] (p'code 2587955)
- Atenolol (Atenolol AFT S29) oral liq 25 mg per 5 ml, 300 ml OP – restricted to children under 12 years of age – S29 (p'code 2586096)
- Fentanyl (Fentanyl GH) inj 50 mcg per ml, 2 ml ampoule – only on a controlled drug form – no patient co-payment payable – safety medicine; prescriber may determine dispensing frequency – S29 and wastage claimable (p'code 2590190)
- Olopatadine (Olopatadine Teva) eye drops 0.1%, 5 ml OP (p'code 2588048)
- Povidone iodine (Betadine) oint 10%, 65 g OP – maximum of 130 g per prescription and only on a prescription (p'code 2159252)
- Terbutaline sulphate (Bricanyl Turbuhaler) powder for inhalation, 200 mcg per dose (equivalent to 250 mcg metered dose), breath activated, 120 dose OP (p'code 2578417)
- Tobramycin (TOBI) solution for inhalation 60 mg per ml, 5 ml – subsidy by endorsement – wastage claimable, Pharmacode change (p'code 2578891)

Changes to restrictions, chemical names and presentations

- Alglucosidase alfa (Myozyme) inj 50 mg vial – amended Special Authority criteria
- Betaine (Cystadane) powder for oral soln, 180 g OP – amended Special Authority criteria
- Carbohydrate – amended Special Authority criteria
- Clarithromycin tab 250 mg (Apo-Clarithromycin) and grans for oral liq 250 mg per 5 ml (Klacid) – amended restrictions
- Flecainide acetate (Flecainide BNM) tab 50 mg – brand switch fee removed
- Galsulfase (Naglazyme) inj 1 mg per ml, 5 ml vial – amended Special Authority criteria
- HMG CoA Reductase Inhibitors (Statins) – prescribing guidelines removed
- Hydroxychloroquine (Plaquenil) tab 200 mg – amended subsidy by endorsement
- Hyoscine hydrobromide (Scopoderm TTS) patch 1.5 mg – amended Special Authority criteria
- Nintedanib (Ofev) cap 100 mg and 150 mg – amended Special Authority criteria
- Pirfenidone (Esbriet) tab 801 mg and cap 267 mg – amended Special Authority criteria
- Povidone iodine (Betadine) oint 10%, 25 g OP and 65 g OP – amended maximum prescription quantity

- Sapropterin dihydrochloride (Kuvan) tab soluble 100 mg, 30 OP
– amended Special Authority criteria
- Sodium phenylbutyrate (Pheburane) grans 483 mg per g, 174 g OP – amended Special Authority

Increased subsidy

Chemical	Presentation	Fully subsidised brands
Acipimox	Cap 250 mg	Olbetam
Calcium folinate	Tab 15 mg	DBL Leucovorin Calcium
Dacarbazine	Inj 200 mg vial Inj 200 mg for ECP	DBL Dacarbazine Baxter
Dantrolene	Cap 25 mg	Dantrium Dantrium S29
Daunorubicin	Inj 2 mg per ml, 10 ml	Pfizer
	Inj 20 mg for ECP, 20 mg OP	Baxter
Diazepam	Rectal tubes 5 mg	Stesolid
Ibuprofen	Tab long-acting 800 mg	Brufen SR
Mitomycin C	Inj 5 mg vial	Teva
	Inj 1 mg for ECP	Baxter
Promethazine hydrochloride	Inj 25 mg per ml, 2 ml ampoule	Hospira
Rifabutin	Cap 150 mg	Mycobutin
Vincristine sulphate	Inj 1 mg per ml, 2 ml vial	DBL Vincristine Sulfate
	Inj 1 mg for ECP	Baxter

Decreased subsidy

Chemical	Presentation	Fully subsidised brands	Partially subsidised brands
Etanercept	Inj 25 mg	Enbrel	
	Inj 50 mg autoinjector		
	Inj 50 mg prefilled syringe		